In the past years, many research projects at Creative Biolabs were aimed to develop sdAb-tracers for imaging of membrane cancer biomarkers. Examples of successful projects include those targeting epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), hepatocyte growth factor (HGF) and carcinoembryonic antigen (CEA) in different tumor models. Creative Biolabs is currently expanding our services & products list of oncology tracers in collaboration with strategically-chosen academic and industrial partners. Due to their small size, high thermal and chemical stability, nanomolar-range affinities, high specificity, and fast blood clearance, sdAbs should preferentially be selected for tumor in vivo imaging. Besides ready-to-use catalogue, Creative Biolabs makes full advantages of different labels and provides customized sdAb-based tracers (Nanotracers) development services for in vivo cancer biomarkers imaging research.
EGFR is overexpressed in a variety of human tumors such as non-small cell lung cancer, breast, gastric, colorectal, bladder, renal, pancreatic, and ovarian cancers. Studies reported that anti-EGFR sdAb were evaluated as tracers for imaging of EGFR-positive xenografted tumors in mice. 99mTc-labeled sdAbs were cleared very fast out of blood and non-target organs and accumulated in A431 EGFR-positive tumors but not in EGFR-negative R1M tumors with high tumor-to-organ ratios.
CEA is a biomarker for multiple cancer types, including colorectal carcinoma and adenocarcinomas of the lung, breast, other gastrointestinal organs and the ovaries. It is the target of the clinically-approved imaging tracer CEA-Scan, a 99mTc-labeled Fab fragment. SdAbs have also been successfully used to image CEA-positive xenografted tumors. For instance, the CEA specific sdAb (CEA1) was radiolabeled with 99mTc. Biodistribution and SPECT imaging studies in mice bearing CEA-positive human colon adenocarcinoma (LS174T) tumor showed both hepatic and renal clearance of the radiolabeled sdAb, resulting in low blood radioactivity levels.
HER2 is a biomarker for breast and other types of cancers. Anti-HER2 sdAbs have been generated and biochemically evaluated for strength and specificity of antigen recognition, stability, targeted epitope and internalization rate. Different labels such as 99mTc, 68Ga, 89Zr, IRDye800CW have been used for in vivo sdAb-based radiopharmaceuticals evaluation.
Elevated levels of HGF and c-Met have been observed in most solid tumors and are associated with increased aggressiveness of tumors. The potential of sdAbs for PET imaging of HGF-expressing tumors was reported. Two sdAbs, 1E2 and 6E10, were each molecularly fused to albumin-binding units (Alb8), conjugated with Df-Bz-NCS chelator and radiolabeled with 89Zr.
Imaging Field | Target | Antibody | Radiolabel | Related Disease | Notes |
Tumor Cell Imaging | HER2 | 2Rs15d | 99mTc, 111In, 177Lu, 18F, 225Ac, 68Ga, 131I | Breast Cancer |
Ready to Use Nano-Imaging Tracer Products |
5F7 | 125I, 131I, 18F | Breast Cancer | |||
EGFR | 7C12, 7D12 | 99mTc, 177Lu, 68Ga, 89Zr | Skin Cancer | ||
D10 | 99mTc | Skin Cancer | |||
PSMA | PSMA30 | 99mTc | Prostate Cancer | ||
JVZ-007 | 111In | ||||
CEA | CEA5 | 99mTc | Breast Cancer | ||
CD20 | 9077, 9079 | 99mTc, 111In, 177Lu, 68Ga | Non-Hodgkin lymphoma | ||
HGF | 1E2-Alb8, 6E10-Alb8 | 89Zr | Glioma |
If you are interested in our Nanotracer tool development and imaging services, please directly contact us and consult our technical supports online.
For Research Use Only.